Market Overview

Barclays Raises Price Target on Herbalife to $94, Cites Buyback Plan, Business Model in China

Related HLF
Ackman: Allergan Is A Good Merger Arbitrage Play, Potential 28% Upside
Bill Ackman Says Herbalife's Business Is Declining
Global Jitters Send Wall Street Tumbling (Fox Business)

Meredith Alder of Barclays appeared optimistic on Herbalife (NYSE: HLF) shares in a research note Tuesday morning. The analyst boosted her price target from $78 to $94 while maintaining an Overweight rating.

Adler attributed the boosted price target to her assumption for a large buyback plan (to the tune of $1.5 billion in shares) from Herbalife this year and also related to the company's business model in China.

The Barclays analyst believes Herbalife's business in China will be "unique" and "tightly controlled." She appears confident the issues with Nu Skin (NYSE: NUS) will not affect Herbalife in a “material way."

Alder adjusted her 2014 EPS estimate from $5.65 to $6.27 in the note. The analyst consensus estimate currently sits at $5.76.

With Herbalife shares up 1.3 percent to $71.11 at last check, Alder's new price target represents potential upside of about 32 percent.

Latest Ratings for HLF

DateFirmActionFromTo
Nov 2014BarclaysMaintainsOverweight
Nov 2014BTIG ResearchInitiates Coverage onBuy
Nov 2014SunTrust Robinson HumphreyDowngradesBuyNeutral

View More Analyst Ratings for HLF
View the Latest Analyst Ratings

Posted-In: Analyst Color News Price Target Global Analyst Ratings

 

Related Articles (HLF + NUS)

Around the Web, We're Loving...

Get Benzinga's Newsletters